Johnson & Johnson Other Infectious Diseases — Percent Change (as a percent) increased by 108.8% to 18.6% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 118.5%, from -100.8% to 18.6%. This is a positive signal — higher values indicate stronger performance for this metric.
Positive growth signals strong market adoption or successful lifecycle management, whereas negative growth suggests market saturation, loss of exclusivity, or competitive displacement.
This metric measures the period-over-period percentage growth or decline in net sales for the Other Infectious Diseases...
Comparable to organic revenue growth rates reported by pharmaceutical peers for specific therapeutic sub-segments or niche product portfolios.
jnj_segment_other_infectious_diseases_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -16.7% | -55.4% | 0.1% | -81.6% | -60.5% | -85.9% | -50.5% | -44.3% | -136.7% | -30.2% | -100.8% | -88.7% | -212.1% | 18.6% |
| QoQ Change | — | -231.7% | +100.2% | <-999% | +25.9% | -42.0% | +41.2% | +12.3% | -208.6% | +77.9% | -233.8% | +12.0% | -139.1% | +108.8% |
| YoY Change | — | — | — | -388.6% | -9.2% | <-999% | +38.1% | +26.8% | — | +40.2% | -127.5% | +35.1% | -602.3% | +118.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.